ArticleFrontiers in cardiovascular medicine2025
Transcatheter pulmonary valve replacement with the venusP-valve system in a patient with double outlet right ventricle and transposition of the great arteries a first-in-human case report.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Taussig-Bing anomaly is a rare form of double outlet right ventricle (DORV) characterized by complex physiology, often requiring multiple surgeries. This report describes the use of the VenusP-Valve System ina 36-year-old patient with Taussig-Bing anomaly, transposition of the great arteries (TGA), and prior surgical interventions including Blalock-Taussig shunt, arterial switch, and ventricular septal defect (VSD) closure. The patient presented with atrial fibrillation, baseline clinical signs of right-sided heart failure (jugular venous distension, edema, holosystolic murmur), New York Heart Association (NYHA) III symptoms, severe tricuspid regurgitation (TR), residual VSD, and significant pulmonary stenosis. Right-heart catheterization revealed an extremely high baseline Qp/Qs of 10.4, derived by the Fick method with oxygen consumption estimation and mixed venous sampling; this value was interpreted as artifact-influenced, and normalized to ∼2 after medical optimization. After multidisciplinary discussion, a transcatheter pulmonary valve replacement (TPVR) using the VenusP-Valve System was successfully performed. At 30 days, the patient improved to NYHA II with no major complications, reduction of TR to moderate, and stable residual VSD shunt (Qp/Qs ∼2). This case highlights the feasibility and clinical utility of VenusP-Valve in managing complex congenital heart disease, particularly in enlarged, irregular, patch-augmented right ventricular outflow tracts (RVOTs) not suitable for balloon-expandable or hourglass-anchoring valves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.